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Abstract
Background: Pancreatic adenosquamous carcinoma has a poor prognosis, with limited prospective trial data to
guide optimal treatment. The potential impact of drug metabolism on the treatment response of patients with
pancreatic adenosquamous carcinoma is largely unknown.
Case presentation: We describe the case of a 51 year old woman with pancreatic adenosquamous carcinoma
who, following surgical resection, experienced early disease relapse during adjuvant gemcitabine therapy.
Paradoxically, this was followed by an exceptional response to capecitabine therapy lasting 34.6 months. Strong
expression of cytidine deaminase was detected within the tumour.
Conclusions: This case study demonstrates that early relapse during adjuvant chemotherapy for pancreatic
adenosquamous carcinoma may be compatible with a subsequent exceptional response to second line
chemotherapy, an important observation given the poor overall prognosis of patients with adenosquamous
carcinoma. Cytidine deaminase is predicted to inactivate gemcitabine and, conversely, catalyze capecitabine
activation. We discuss strong intra-tumoural expression of cytidine deaminase as a potential mechanism to explain
this patient’s disparate responses to gemcitabine and capecitabine therapy, and highlight the benefit that may be
gained from considering similar determinants of response to chemotherapy in clinical practice.
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Background
Pancreatic adenosquamous carcinoma is estimated to ac-
count for fewer than 10% of all pancreatic exocrine malig-
nancies (reviewed in [1]). It is associated with a poor
prognosis, with a median survival of 4 months (95% CI, 3–
6months) or 12months (95% CI, 8–52months) post-
resection in cases of early stage disease [2]. The use of adju-
vant chemotherapy is supported by retrospective analyses
[2–4], commonly with single agent gemcitabine or 5-
fluorouracil according to the evidence base for the treat-
ment of the broader group of pancreatic exocrine malig-
nancies [5, 6] . The optimal management of progressive
disease during adjuvant chemotherapy in patients with ade-
nosquamous carcinoma is unknown. We describe the case
of a patient with adenosquamous carcinoma experiencing
disease progression during adjuvant gemcitabine therapy.
Case presentation
A previously well 51 year old white Caucasian woman pre-
sented with sudden onset right upper quadrant abdominal
pain. She took no regular medication and had no medical,
surgical or family history of note. Unenhanced computerised
tomography (CT) imaging, used due to a pre-existing iodine
allergy, identified a 4 cm mass in the head of the pancreas
associated with marked pancreatic and mild bile duct dilata-
tion (Fig. 1a). Magnetic resonance (MR) imaging of the liver
with gadolinium contrast demonstrated a 4.4 × 3.9 cm mass
arising from the inferior head and uncinate process of the
pancreas, abutting the superior mesenteric vein (SMV) but
with no evidence of liver, peritoneal or mesenteric involve-
ment (Fig. 1b). Positron emission tomography-CT identified
metabolically active disease limited to the head of the pan-
creas. Endoscopic ultrasound guided fine needle aspiration
demonstrated poorly differentiated malignancy, with evi-
dence of epithelial and neuroendocrine differentiation with
weak chromogranin and focal cytokeratin staining.
At this point the Eastern Cooperative Oncology Group
Performance Status (ECOG PS) of the patient was 0. A pan-
creaticoduodenectomy with SMV resection was performed.
Histology confirmed a biphasic carcinoma with adenosqua-
mous and undifferentiated components (Fig. 1c-e); the un-
differentiated component was positive for CD56 but
negative for other neuroendocrine markers (synpatophysin
and chromogranin) and exhibited focal pancytokeratin stain-
ing. There was evidence of perineural and lymphovascular
space invasion, and 3 out of 25 lymph nodes contained
Fig. 1 Head of pancreas carcinoma with adenosquamous and undifferentiated components; (a) unenhanced CT demonstrating a mass at the
head of the pancreas with marked pancreatic duct dilatation (solid arrow); (b) Coronal MRI (with gadolinium contrast) demonstrating head of
pancreas mass (solid arrow) abutting the adjacent SMV (dashed arrow); (c) hematoxylin and eosin stain of head of pancreas tumour from
Whipple’s resection demonstrating a biphasic carcinoma with adenosquamous (magnified in (d)) and undifferentiated (magnified in
(e)) components
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metastatic adenosquamous carcinoma. Resection margins
were clear of disease. Staging was confirmed as pT3 pN1
M0 R0 (American Joint Committee on Cancer Stage IIB).
Post-operatively, adjuvant gemcitabine (1000mgm− 2 on
days 1, 8 and 15 of a 28-day cycle) chemotherapy was ad-
ministered as part of the European Study Group for Pan-
creatic Cancer (ESPAC) 4 Trial (UKCRN ID 4307;
ISRCTN96397434). However, after the second cycle of
gemcitabine, the patient reported further right upper quad-
rant pain. ECOG PS dropped to 1 and unenhanced CT
confirmed multiple hypodense liver lesions of new onset in
keeping with liver metastases (Fig. 2a liver at point of diag-
nosis; Fig. 2b new liver metastases). Gemcitabine was
stopped and palliative capecitabine started (1250mgm− 2
with an 18% dose reduction at patient request to reduce
tablet burden). Persistent anaemia, thrombocytopenia and
coagulopathy were managed with frequent transfusions of
packed red blood cells (PRBC) and oral tranexamic acid.
After 19 weeks of capecitabine therapy ECOG PS
returned to 0, and the patient returned to work full time.
Fig. 2 Radiological progression of liver metastases, by unenhanced CT. a baseline liver free of metastatic disease; b new liver lesions in segments
7 and 8 (solid arrows) 1.8 months into gemcitabine therapy; c high attenuation calcification of pre-existing liver lesions (solid arrows) and further
low attenuation cystic components (dashed arrow) 13.8 months into capecitabine therapy; d stable liver disease 32.3 months into capecitabine
therapy; e increase in size of segment 8 liver lesion (solid arrow) 34.6 months into capecitabine therapy; f stable liver disease 13.3 months into
modified FOLFIRINOX therapy
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Haematological indices improved. No further PRBC trans-
fusions were required after 24 weeks and tranexamic acid
was stopped. Palmar-plantar erythrodysesthesia, 14.6
months into capecitabine therapy, prompted a switch to a
2 week on, 2 week off treatment schedule which was well
tolerated. Restaging CTs after 13.8 and 32.3months of
capecitabine therapy confirmed stable, measurable disease,
but with marked calcification of liver metastases, indica-
tive of disease response (Fig. 2c, d). After 34.6 months (41
cycles) of capecitabine monotherapy, the patient reported
recurrent right upper quadrant pain. A CT confirmed pro-
gressive disease (Fig. 2e) with an increased soft tissue com-
ponent surrounding the pre-existing calcification within
segment 8, in keeping with progressive disease.
Capecitabine was discontinued and FOLFIRINOX chemo-
therapy (5-FU 400mgm− 2 bolus followed by 2400mgm− 2
infusion over 46 h; irinotecan 180mgm− 2; oxaliplatin 85
mgm− 2) started, with granulocyte-colony stimulating factor
(GCSF) support. Due to peripheral neurotoxicity, the oxali-
platin dose was reduced by 20% for cycle 7 and discontinued
from cycle 8. The patient completed 12 cycles of the re-
duced intensity chemotherapy. An end of treatment CT
demonstrated stable partially calcified liver metastases, and
this was followed by a treatment break. Surveillance CT
13.3months after initiating FOLFIRINOX and 4 years 5.3
months after initial presentation, confirmed stable disease
(Fig. 1f).
To better understand the treatment responses observed
and to explore future treatment options, tumor targeted
DNA sequencing, tumour CDA expression, and whole
blood CDA activity were analyzed. Genetic analysis identi-
fied a G12D mutation in KRAS, a truncating mutation in
TP53, but no BRCA1/ BRCA2 mutations or currently puta-
tive “druggable” mutations [7]. Strong expression of CDA
was detected within the glandular and, to a lesser extent,
the undifferentiated components of the tumor by immuno-
histochemistry (Fig. 3a, b). Whole blood CDA activity via
spectrophotometry was found to be 6.72 UA/mg protein,
below the median CDA activity level observed in this pa-
tient population ([8] and unpublished data).
Discussion and conclusions
The poor prognosis of patients with pancreatic adenos-
quamous carcinoma may impact on the decision to con-
sider second line chemotherapy. In the case described,
despite early relapse during adjuvant gemcitabine ther-
apy, the patient proceeded to have a 34.6 month remis-
sion on second line capecitabine. This is an exceptional
response. To our knowledge, this is the first documented
case of a patient with adenosquamous cancer having an
exceptional response to second line treatment, in the
context of early disease relapse.
CDA mediates the inactivation of gemcitabine [9] and,
conversely, the activation of capecitabine [10]. Relative to
the normal pancreas, it has been reported that CDA is
overexpressed in pancreatic cancer [11]. Both circulating
CDA activity [12, 13], and intra-tumoural expression of
CDA [8, 14, 15], varies between patients and may impact
on the response of patients to gemcitabine and / or cape-
citabine therapy. Whereas low circulating CDA activity has
been associated with a better response to gemcitabine
treatment in patients with pancreatic cancer in two studies
[12, 13], this was not the case in a subsequent multicentre
prospective trial with 120 patients treated with gemcitabine
[16]. For intra-tumoural CDA expression, preclinical data
have identified strong expression to be associated with re-
duced response to gemcitabine [14] and increased response
to capecitabine [15]. Clinical data investigating the impact
of intra-tumoural CDA activity are lacking, although data
from a recent study of 105 patients with pancreatic cancer
do suggest that intra-tumoural CDA expression may be
predictive of response to sequential, but not concomitant,
therapy with nab-paclitaxel and gemcitabine in the first
line setting [8]. Germline CDA single nucleotide polymor-
phisms have also been associated with CDA activity and /
or toxicity or survival with gemcitabine based therapy [17–
19]. However, CDA single nucleotide polymorphisms are de-
tected in only a subset of patients with reduced CDA activity,
supportive of other regulatory mechanisms determining
Fig. 3 CDA protein expression within adenosquamous and
undifferentiated tumour components. Formalin-fixed paraffin-
embedded sections of adenosquamous (a) and undifferentiated (b)
tumour components were stained with a polyclonal rabbit anti-CDA
antibody (Epitomics) on a Leica BOND-MAX Autostainer (Leica
Biosystems, UK), with heat-induced epitope retrieval with pH 6.0
citrate-based solution (ER1, Leica Biosystems, UK)
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CDA expression and activity (reviewed in [20]). In this case
report, we identify strong intra-tumoural expression of CDA
as a potential contributor to the patient’s disparate responses
to these two chemotherapeutic agents. Importantly, whole
blood CDA activity was not elevated, indicating that in-
creased CDA activity was not systemic, and capecitabine was
well tolerated. Similar consideration, and reporting, of how
intra-tumoural drug metabolism may impact on responses
to chemotherapy will facilitate our understanding of these re-
sponses and our treatment decisions in the future.
The choice of adjuvant chemotherapy for pancreatic
adenosquamous cancer has, to date, been largely guided
by trials conducted almost exclusively in patients with
pancreatic adenocarcinoma [21–24]. Data from the
ESPAC-4 trial suggest that combination therapy with
gemcitabine and capecitabine may offer further survival
benefit over single agent [23]. Conversely, retrospective
analyses restricted to pancreatic adenosquamous cancer
have suggested that this subgroup may be most respon-
sive to combination therapy with platinum agents [3, 4].
Whilst evidence supporting the optimal adjuvant regi-
men for pancreatic adenosquamous tumors remains lim-
ited by the relatively low incidence of the disease, this
case report demonstrates that early relapse on one regi-
men may be compatible with a subsequent exceptional
response to second line chemotherapy, particularly when
a biochemical rationale exists for the failure of initial
chemotherapy.
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